1
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Marc J Ostro, Micrea C Popescu: Stable plurilamellar vesicles, their preparation and use. The Liposome Company, Pennie & Edmonds, June 11, 1985: US04522803 (204 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.


2
Michael W Fountain, Steven J Weiss, John J Kearns, Alan L Weiner, Mircea C Popescu: Lipid matrix carriers for use in drug delivery systems. The Liposome Company, Pennie & Edmonds, September 9, 1986: US04610868 (142 worldwide citation)

Lipid matrix carriers are described which provide for the sustained release of bioactive agents in vivo or in vitro. The properties of the lipid matrix carriers of the present invention include high entrapment efficiencies; release of entrapped compounds in their active form; biodegradability and av ...


3
Michael W Fountain, Steven J Weiss, Mircea C Popescu: Lipid vesicles prepared in a monophase. The Liposome Company, Pennie & Edmonds, May 13, 1986: US04588578 (132 worldwide citation)

A process for the preparation in a monophasic solvent system of a new type of lipid vesicles, called monophasic lipid vesicles (MPVs). MPVs can be made to encapsulate one or more bioactive agents. MPVs are stable during storage and can be used in vivo in the treatment of disease.


4
Andrew S Janoff, Pieter R Cullis, Marcel B Bally, Michael W Fountain, Richard S Ginsberg, Michael J Hope, Thomas D Madden, Hugh P Schieren, Regina L Jablonski: Dehydrated liposomes. The Liposome Company, Allen Bloom, Catherine L Kurtz, November 14, 1989: US04880635 (98 worldwide citation)

Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at both the inside and outside surfaces of the liposome membranes. F ...


5
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Ronald G Ort, December 8, 1992: US05169637 (71 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


6
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Thomas M Saunders, Ronald G Ort, July 9, 1991: US05030453 (68 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


7
Michael W Fountain: Method for making solvent dilution microcarriers. Fountain Pharmaceuticals, Richards Medlock & Andrews, December 14, 1993: US05269979 (52 worldwide citation)

A method for forming vehicles for encapsulating passenger molecules which have been named solvent dilution microcarriers (SDMCs), and the products of this process, are disclosed which allows for immediate or delayed formation of the encapsulating vehicles following creation of a shelf-stable formed ...


8
Andrew S Janoff, Mircea C Popescu, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Catherine L Kurtz, October 22, 1991: US05059591 (49 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


9
Michael W Fountain, Steven J Weiss, Robert P Lenk, Mircea C Popescu, Richard S Ginsberg: Enhancement of pharmaceutical activity. The Liposome Company, Allen Bloom, Thomas S Saunders, Ronald G Ort, March 19, 1991: US05000958 (38 worldwide citation)

The invention encompasses mixtures of antimicrobial agents coencapsulated in liposomes which when administered in vivo exert an enhanced therapeutic effect. The therapeutic effectiveness of the coencapsulated antimocrobial agents is greater than that of the same combination administered either in so ...


10
Andrew S Janoff, Pieter R Cullis, Marcel B Bally, Michael W Fountain, Richard S Ginsberg, Michael J Hope, Thomas D Madden, Hugh P Schieren, Regina L Jablonski: Methods of dehydrating, storing and rehydrating liposomes. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, July 13, 1999: US05922350 (35 worldwide citation)

Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at both the inside and outside surfaces of the liposome membranes. F ...